Join Deva Dalporto of MyLifeSuckers and Kenneth Mendez, CEO and president of the Asthma and Allergy Foundation of America (AAFA), for a Facebook Live discussion about parent insights on the social, emotional and financial impact of food allergies. Also get helpful Halloween safety tips for parents of kids with food allergies! (Kids With Food Allergies is a division of AAFA.)
On Sept. 13, 2019, the U.S. Food and Drug Administration’s (FDA) Allergenic Products Advisory Committee recommended the approval of Aimmune Therapeutics’ peanut treatment, Palforzia. If approved, Palforzia would be ground-breaking for the future of food allergy treatments. What Is Palforzia? Palforzia, also known as AR101, is a type of oral immunotherapy (OIT) for peanut allergy. If approved, it would be the first FDA-approved treatment for peanut allergy. Currently, some allergists already...
On Sept. 12, 2019, New York Governor Andrew Cuomo signed Elijah's Law (S.218B/A.6971B). Under this law, New York child day care programs have to follow guidelines for preventing and responding to severe food allergy reactions.
In August 2019, the Asthma and Allergy Foundation of America (AAFA) released their My Life With Food Allergy Parent Survey Report. The report highlights the significant social, emotional and financial impact food allergies can have on parents. Our findings also revealed that many children do not receive epinephrine when they are having a severe allergic reaction for many reasons. We asked Dr. Michael Pistiner, pediatric allergist at MassGeneral, to talk about these findings.
States that have policies in place to protect children with allergies and asthma made our 2019 State Honor Roll™ of Asthma and Allergy Policies for Schools (SHR). In the SHR, the Asthma and Allergy Foundation of America (AAFA) identifies states that have comprehensive laws and policies aimed at keeping children with asthma and allergies healthy at school. (KFA is a division of AAFA.)
From 2008 to 2016, the overall incidence of emergency department visits for anaphylaxis saw a 2.3-fold increase, with the greatest increase occurring in children under five years of age, according to a recently published article in The Journal of Allergy and Clinical Immunology: In Practice (JACI: In Practice), an official journal of the AAAAI.
On Aug. 21, 2019, Kenny Mendez, President and CEO of the Asthma and Allergy Foundation of America (AAFA), co-hosted a Facebook Live session with blogger Anna Luther of My Life and Kids. If you didn’t have a chance to tune in live, you can watch a replay of session. (Kids With Food Allergies is a division of AAFA.)
Teva Pharmaceutical Industries (NYSE and TASE: TEVA) today announced availability of the FDA-approved generic version of EpiPen Jr® (epinephrine injection, USP) Auto-Injector, 0.15 mg, in the U.S. The product is available in most retail pharmacies, and the Wholesale Acquisition Cost is $300 for a 2-pack.
Our report – the My Life With Food Allergy: Parent Survey Report – gives a summary of the emotional, social and financial impact on the parent or caregiver of a child with food allergies. Read more about the findings.
Illinois Governor J.B. Pritzker signed a law on Aug. 9, 2019, that would require health insurance policies in his state to cover epinephrine injectors for children 18 and younger. House Bill 3435 will be effective on Jan. 1, 2020.
Join Anna Luther of My Life and Kids Blog and Kenny Mendez, president and CEO of the Asthma and Allergy Foundation of America (AAFA) and Kids With Food Allergies (KFA), a division of AAFA, for a Facebook Live discussion on new research and insights on the social and emotional impact of food allergies on parents. Also get useful back-to-school advice for parents of kids with food allergies!
Windgap Medical, Inc. announced today that it has a strategic partnership with ALK-Abelló, A/S ("ALK") to commercialize the company's epinephrine autoinjector (EAI) for the treatment of anaphylactic shock.
DBV Technologies, a clinical-stage biopharmaceutical company, today announced the submission of its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for Viaskin® Peanut for the treatment of peanut-allergic children ages 4 to 11 years.
Recently, the FDA has been asking for more data to support adding sesame to the list of top food allergens. A new study titled “Prevalence and Severity of Sesame Allergy in the United States” has been released by the JAMA Network today in response to the FDA’s request.
While experimental desensitization strategies are available in research settings, people with food allergies must avoid known allergens and are advised to carry injectable epinephrine to prevent potentially life-threatening allergic reactions caused by accidental exposures. To help alleviate this risk, a new study to evaluate an experimental treatment for food allergy launched today.